An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion

BACKGROUND: Products cryopreserved with dimethyl sulfoxide (DMSO) in stem cell transplant (SCT) often cause many adverse effects during their infusion (major cardiovascular events, dyspnea … even death). These are especially frequent in pediatric patients. We tested if a fully automated and closed wash procedure (Sepax S‐100, Biosafe) allowed us to maintain the absolute CD34+ cell number, cell viability, and engraftment potential, decreasing the untoward reactions.

[1]  M. Cairo,et al.  Determining post‐thaw CD34+ cell dose of cryopreserved haematopoietic progenitor cells demonstrates high recovery and confirms their integrity , 2008, Vox sanguinis.

[2]  H. Kim,et al.  Post‐thaw viable CD34+ cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation , 2007, Vox sanguinis.

[3]  P. Wernet,et al.  Separation of adult bone marrow mononuclear cells using the automated closed separation system Sepax. , 2008, Cytotherapy.

[4]  P. Saas,et al.  Cord blood volume reduction using an automated system (Sepax) vs. a semi-automated system (Optipress II) and a manual method (hydroxyethyl starch sedimentation) for routine cord blood banking: a comparative study. , 2007, Cytotherapy.

[5]  A. Hubel,et al.  Cryopreservation of hematopoietic and non-hematopoietic stem cells. , 2006, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[6]  Luciano Rodríguez,et al.  Evaluation of an automated cell processing device to reduce the dimethyl sulfoxide from hematopoietic grafts after thawing , 2005, Transfusion.

[7]  J. García,et al.  Washing of cord blood grafts after thawing: high cell recovery using an automated and closed system * , 2004, Vox sanguinis.

[8]  S. Glück,et al.  The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  T. Goecke,et al.  Cord blood processing with an automated and functionally closed system , 2003, Transfusion.

[10]  O. Bruserud,et al.  No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide. , 2003, Journal of hematotherapy & stem cell research.

[11]  S. Heimfeld,et al.  A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch , 2003, Bone Marrow Transplantation.

[12]  Øystein Bruserud,et al.  Cryopreserving human peripheral blood progenitor cells with 5‐percent rather than 10‐percent DMSO results in less apoptosis and necrosis in CD34+ cells , 2002, Transfusion.

[13]  A. Donnenberg,et al.  Viability of cryopreserved BM progenitor cells stored for more than a decade. , 2002, Cytotherapy.

[14]  N. Beauchamp,et al.  Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells , 2000, Bone Marrow Transplantation.

[15]  G. Martinelli,et al.  Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases , 1999, Bone Marrow Transplantation.

[16]  K. Takagi,et al.  Effects of long-term cryopreservation on hematopoietic progenitor cells in umbilical cord blood , 1999, Bone Marrow Transplantation.

[17]  H. Jouault,et al.  Successful cryopreservation of purified autologous CD34+ cells: influence of freezing parameters on cell recovery and engraftment , 1998, Bone Marrow Transplantation.

[18]  S. Heimfeld,et al.  A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. , 1997, Blood.

[19]  F. Morabito,et al.  Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. , 1996, Haematologica.

[20]  J. Adamson,et al.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Chen,et al.  Cardiac arrhythmia after infusion of cryopreserved stem cells. , 1994, Bone marrow transplantation.

[22]  E. Otheo,et al.  Cardiovascular toxicities related to the infusion of cryopreserved grafts: results of a controlled study. , 1994, Bone marrow transplantation.

[23]  C. Le Forestier,et al.  A simple, efficient washing procedure for cryopreserved human hematopoietic stem cells prior to reinfusion. , 1991, Bone marrow transplantation.

[24]  D. Stroncek,et al.  Adverse reactions in patients transfused with cryopreserved marrow , 1991, Transfusion.

[25]  S. Piantadosi,et al.  Clinical toxicity of cryopreserved bone marrow graft infusion. , 1990, Blood.